Drugs /
pimasertib
Back to Drugs List
Associated Genetic Biomarkers
Overview
Generic Name(s):
pimasertib
NCI Definition [1]:
An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity. Pimasertib selectively binds to and inhibits the activity of MEK1/2, preventing the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.
Clinical Trials
Pimasertib has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pimasertib, 1 is phase 1/phase 2 (1 open).
Malignant solid tumor is the most common disease being investigated in pimasertib clinical trials [2].
Drug Details
Synonyms [2]:
as703026, msc1936369b, as 703026, n-[(2s)-2,3-dihydroxypropyl]-3-[(2-fluoro-4- iodophenyl)= amino]isonicotinamide hydrochloride, n-[(2s)-2,3-dihydroxypropyl]-3-[(2-fluoro-4- iodophenyl)amino]isonicotinamide hydrochloride, msc1936369, pimasertib, mek inhibitor as703026, as-703026, emd 1036239
Drug Categories [2]:
MEK inhibitors, Serine/threonine kinase inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
MAP2K1, MAP2K2
NCIT ID [1]:
C84864
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
